Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Subscribe To Our Newsletter & Stay Updated
